Takeda Funds Celiac Asset As Prelude To Potential Acquisition
Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.
You may also be interested in...
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.